research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
Search
for
Sort by
Research
270-300 / 1000+ resultsresearch Tratamientos fitoterapeúticos para la hipertrofia benigna de próstata: serenoa repens
Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
research Effect of the gonadotrophin releasing hormone analogue, goserelin, and oestradiol replacement on sebum excretion rates and hair size in mildly hirsute women
Goserelin and oestradiol treatment slightly improved hairiness but did not significantly change sebum production or hair characteristics in mildly hirsute women.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Raltegravir-Induced Alopecia in an HIV+ Patient
Raltegravir may cause hair loss in some patients.
research Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study
Using electronic health records can help identify drug side effects but has some limitations.
research How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Offenders: Consider Patient Factors When Choosing Off-Label Hormonal and Nonhormonal Agents
Choose treatments for sex offenders based on individual needs, using hormonal and nonhormonal options to reduce sexual drive.
research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.
research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research In situ detection of retinoid-X receptor expression in normal and psoriatic human skin
RXR-alpha is strongly expressed in both normal and psoriatic skin and may help in skin cell differentiation and hair growth.
research Chapter 17. Selective androgen receptor modulators (SARMs)
Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.
research An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
research Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.
Valproic acid is an effective and safe first-choice treatment for many types of seizures.
research Chemotherapy of psoriasis and other skin disorders with oral retinoids
Oral retinoids are effective for treating severe skin disorders but have reversible side effects and risks for pregnant women.
research Phenytoin associated alopecia: drug induced lupus.
Phenytoin, a medication, can cause hair loss and trigger a condition similar to lupus.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
Compound 7p shows strong potential as an anticancer agent.
research Pharmacovigilance in Pediatric Patients with Epilepsy Using Antiepileptic Drugs
Most children with epilepsy on antiepileptic drugs experience side effects, especially those on multiple drugs, but these drugs help reduce seizures.
research ZINC, Copper and Chromium Contents in Schizophreinc Hair of Korean
People with schizophrenia have lower zinc, copper, and chromium in their hair.
research SARMS vs. anabolic steroids: comparative analysis of mechanisms, effects and health implications
research UNITY INOVA NMR Spectrometer Systems Installation Planning
Divalproex sodium significantly improved headaches in two-thirds of patients.
research S4890 Infliximab-Induced Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis Syndrome
Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research PERAN SUPLEMENTASI VITAMIN D PADA TATA LAKSANA SARKOIDOSIS KUTIS
Vitamin D supplements should be used cautiously in sarcoidosis patients, with regular monitoring to avoid high calcium levels.
research Hair loss disorders (alopecias)
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.